Anavex Life Sciences Corp (AVXL)

[hnbadger1]

Great work Mayo! I love the closing statement-

“ Assessment: The top 10 publicly traded biopharmaceutical companies currently trade at an average of 36.14 P/E (Astrazeneca being an outlier at 87.66). When
we combine large market penetration into highly unmet needs like Alzheimer's, Parkinson's, and Rett Syndrome, the potential revenue generated could cause
Anavex to easily surpass $1,000 per share if the company maintains current dilution and doesn't split the stock. If Alzheimer's is approved in 2022/early-2023, I
anticipate potential revenues of over $17-24B annually. With a P/E of 36 and minimal additional dilution, the share price would exceed $6,000. Rett syndrome at
peak sales alone could cause the share price to exceed $700 in similar circumstances. With the extraordinary reward presented with Anavex' clinical success, a
long position in Anavex appears to be exceptionally warranted. All trials to date have had overwhelming efticacy with many transformative catalysts coming
within the next 12 months. As other biotech developing S1R agonists continue expanding, it is increasingly likely S1R platforms will become a healthcare staple.”